Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Lowering beta-amyloid levels in blood to treatment Alzheimer’s

07.01.2003


Agents that alter blood levels of beta-amyloid protein in mouse models of Alzheimer’s disease represent a potential approach to treating the illness in humans that may be safer than the vaccine method of therapy, researchers report in a new study.



Beta-amyloid protein is a component of the amyloid plaques that accumulate in the brains of people with Alzheimer¡’s disease. Beta-amyloid is viewed by many researchers and clinicians as the underlying cause of the degeneration and dementia that characterize the illness. Alzheimer’s disease is a progressive, degenerative brain disease and the most common form of dementia. There is no cure. Approximately four million Americans have the disease and some 14 million are expected to have it by 2050 unless a cure or preventive treatment is found.

"Recent evidence suggests that this protein in the peripheral circulation outside the brain may contribute to its accumulation in the brain," says study co-author Karen Duff, PhD, of the Center for Dementia Research, Nathan Kline Institute/New York University. The study, funded by the National Institutes of Health and the Alzheimer’s Association, appears in the January 1 issue of The Journal of Neuroscience.


If Alzheimer’s disease can effectively be treated by agents that do not need to enter the brain, pharmaceutical companies may be able to develop targeted drugs that have few effects on the central nervous system, she adds. Previous animal studies suggested that one way to do this was through a vaccine that produced antibodies to amyloid. But Elan Corporation and American Home Products ended trials of their immune-based Alzheimer’s vaccine in February 2002 after 15 patients experienced swelling of the central nervous system.

"There’s good medical precedent seen in the treatment of coronary heart disease by administering agents that lower serum cholesterol levels," notes Bradley Hyman, MD, PhD, a neurologist at Massachusetts General Hospital in Boston. "This kind of parallel approach ¨C blocking beta-amyloid accumulation in the brain by binding it to an agent in the bloodstream ¨C represents an extremely viable line of research."

Other scientists, however, suggest the results of such studies be viewed with caution. "Having a substance that acts as a peripheral sink for brain beta-amyloid may simply be shifting the damage from the brain to the vasculature and body itself," says Gary Arendash, PhD, professor of biology and psychology at the University of South Florida. "This approach may trap a considerable amount of beta-amyloid in the cerebral blood vessels, weakening them and leading to cerebral hemorrhage."

In the new study, Duff, Dr. Yasuji Matsuoka and their colleagues injected the beta-amyloid binding agent gelsolin into the peripheral bloodstreams of 13 mice bred to develop Alzheimer’s disease. They also performed sham injections in 16 other mice with the same genetic background. Both groups received injections every two days for three weeks. Upon examination, the brains of mice receiving gelsolin had significantly less beta-amyloid protein than those in the other group. Use of gelsolin also resulted in a significant decrease in the number of brain plaques.

The scientists saw similar results when they used another beta-amyloid binding agent, ganglioside GM1.

"We do not advocate using these particular agents as treatments for Alzheimer’s disease in humans," Duff says. "Rather, we see this as an initial step in the development of compounds that act in this manner, and as proof-of-concept for a prophylactic approach that may be more flexible, more reliable and less likely to cause side effects in long-term administration paradigms than immunization-based therapies."

Duff and Matsuoka’s colleagues in this study include: Mariko Saito, Mitsuo Saito, John LaFrancois, Kate Gaynor, Vicki Olm, Lili Wang, Evelyn Casey, Yifan Lu, Chiharu Shiratori and Cynthia Lemere. Duff, Matsuoka and Lemere are members of the Society for Neuroscience, which publishes The Journal of Neuroscience. SfN is an organization of more than 31,000 basic scientists and clinicians who study the brain and nervous system. Duff can be reached at 845-398-5427; Matsuoka can be reached at
845-398-2175.

Phil Kibak | EurekAlert!
Further information:
http://www.sfn.org/

More articles from Health and Medicine:

nachricht A 'half-hearted' solution to one-sided heart failure
24.11.2017 | Boston Children's Hospital

nachricht New study points the way to therapy for rare cancer that targets the young
22.11.2017 | Rockefeller University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New proton record: Researchers measure magnetic moment with greatest possible precision

High-precision measurement of the g-factor eleven times more precise than before / Results indicate a strong similarity between protons and antiprotons

The magnetic moment of an individual proton is inconceivably small, but can still be quantified. The basis for undertaking this measurement was laid over ten...

Im Focus: Frictional Heat Powers Hydrothermal Activity on Enceladus

Computer simulation shows how the icy moon heats water in a porous rock core

Heat from the friction of rocks caused by tidal forces could be the “engine” for the hydrothermal activity on Saturn's moon Enceladus. This presupposes that...

Im Focus: Nanoparticles help with malaria diagnosis – new rapid test in development

The WHO reports an estimated 429,000 malaria deaths each year. The disease mostly affects tropical and subtropical regions and in particular the African continent. The Fraunhofer Institute for Silicate Research ISC teamed up with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME and the Institute of Tropical Medicine at the University of Tübingen for a new test method to detect malaria parasites in blood. The idea of the research project “NanoFRET” is to develop a highly sensitive and reliable rapid diagnostic test so that patient treatment can begin as early as possible.

Malaria is caused by parasites transmitted by mosquito bite. The most dangerous form of malaria is malaria tropica. Left untreated, it is fatal in most cases....

Im Focus: A “cosmic snake” reveals the structure of remote galaxies

The formation of stars in distant galaxies is still largely unexplored. For the first time, astron-omers at the University of Geneva have now been able to closely observe a star system six billion light-years away. In doing so, they are confirming earlier simulations made by the University of Zurich. One special effect is made possible by the multiple reflections of images that run through the cosmos like a snake.

Today, astronomers have a pretty accurate idea of how stars were formed in the recent cosmic past. But do these laws also apply to older galaxies? For around a...

Im Focus: Visual intelligence is not the same as IQ

Just because someone is smart and well-motivated doesn't mean he or she can learn the visual skills needed to excel at tasks like matching fingerprints, interpreting medical X-rays, keeping track of aircraft on radar displays or forensic face matching.

That is the implication of a new study which shows for the first time that there is a broad range of differences in people's visual ability and that these...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Ecology Across Borders: International conference brings together 1,500 ecologists

15.11.2017 | Event News

Road into laboratory: Users discuss biaxial fatigue-testing for car and truck wheel

15.11.2017 | Event News

#Berlin5GWeek: The right network for Industry 4.0

30.10.2017 | Event News

 
Latest News

IceCube experiment finds Earth can block high-energy particles from nuclear reactions

24.11.2017 | Physics and Astronomy

A 'half-hearted' solution to one-sided heart failure

24.11.2017 | Health and Medicine

Heidelberg Researchers Study Unique Underwater Stalactites

24.11.2017 | Earth Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>